Inventor
SANJAYA SINGH
Inventor
US
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes28%
C07KPeptides28%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C12NMicroorganisms or enzymes10%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
C07HSugars2%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%
PatentTitleYear
12,492,256Methods and compositions for modulating beta chain mediated immunity202512,492,226Materials and methods for producing bioengineered virus specific lymphocytes202512,460,001Proteins comprising CD3 antigen binding domains and uses thereof202512,448,449Immune targeting molecules and uses thereof202512,221,487Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains202512,180,278Antibody targeting CD22 and CD79B202412,134,658Materials and methods for multidirectional biotransportation in virotherapeutics202412,129,310Materials and methods for enhanced linker targeting202412,103,977Trispecific antibody targeting CD79b, CD20, and CD3202412,077,585Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses202412,077,592GPRC5D chimeric antigen receptors and cells expressing the same202412,076,413Compositions and methods for modulating delta gamma chain mediated immunity202412,071,466Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof202411,981,932Materials and methods for the manufacture of pluripotent stem cells202411,965,024Methods and compositions for modulating beta chain mediated immunity202411,926,667Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII202411,897,964Anti-PSGL-1 antibodies and uses thereof202411,884,744Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof202411,866,499Monospecific and multispecific anti-TMEFF2 antibodies and their uses202411,866,501Anti-TrkB antibodies202411,827,708Proteins comprising HLA-G antigen binding domains and their uses202311,680,096Compound targeting IL-23A and TNF-alpha and uses thereof202311,667,712Materials and methods for modulating t cell mediated immunity202311,639,396Antibody binding to a linker peptide202311,434,287Anti-IL13 antibodies and uses thereof202211,384,151CX3CR1-binding polypeptides comprising immunoglobulin single variable domains202211,370,818Anti-BAFF antibodies202211,267,880Anti-Sema3A antibodies and their uses for treating eye or ocular diseases202211,242,394Anti-CD40 antibodies202211,236,155Antibodies to pyroglutamate amyloid-b and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2024Patents assigned to BOEHRINGER INGELHEIM INT (6)· patent assignee history
2022–2025Patents assigned to ABLYNX NV (2)· patent assignee history
2022–2025Based in US· patent location history
2023–2025Patents assigned to JANSSEN BIOTECH INC (19)· patent assignee history
2023–2024Patents assigned to MACROGENICS INC (2)· patent assignee history
2024Patents assigned to ALTRUBIO INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| JANSSEN BIOTECH INC | 19 | 2023–2025 |
| BOEHRINGER INGELHEIM INT | 6 | 2022–2024 |
| ABLYNX NV | 2 | 2022–2025 |
| MACROGENICS INC | 2 | 2023–2024 |
| ALTRUBIO INC | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 30 | 2022–2025 |